Derek Lowe
An Arkansan by birth, Derek got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He’s worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer’s, diabetes, osteoporosis and other diseases.
Derek writes the popular blog In the pipeline on drug discovery and the pharma industry.
OpinionWelcome to the MegaPharm target selection and project resourcing meeting
Overheard recently in a seminar room near you…
OpinionFluorine makes you an offer you can’t refuse
What might we do if we had a new, electron-donating equivalent element?
OpinionMaintaining mental balance
Finding solace from human affairs in the eypiece of a telescope or microscope
OpinionRobots queuing up to fail
Claims of an AI revolution in drug discovery are missing the biggest problem
OpinionLarge language models are great, but they don’t speak to me
AI has some made tremendous achievements, but some things mean more than words
OpinionA chemist in the flower garden
The beautifully complex molecules plants produce are as inspiring as the blooms themselves
OpinionBeing wrong is almost inevitable
On the tightrope of expressing your opinion, you always risk looking a fool
OpinionMedicinal chemistry’s biological blind spots
Despite advances in modern medicine, there are some big gaps in our knowledge
OpinionThe US abortion drugs regulation challenge has stalled, but it will return
Having failed in the US Supreme Court, anti-abortion activists are trying other ways to prevent access to mifepristone
OpinionWill science ever reach an end?
While the rate of discoveries in any field may slow over time, the frontier creeps ever further
OpinionLab automation gives me more time at the top of the mountain
Getting back to the bench reminds Derek Lowe how much has changed in 40 years
OpinionWater isn’t normal
Despite its familiarity, water is a chemical oddity. But that’s what makes it fascinating
OpinionFrom one sinking ship to another?
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
OpinionHarnessing fear and greed for innovation
Many powerful emotions motivate us in the search for new knowledge
OpinionSaving the sounds of Superstition
Preserving the look, feel and sound of degrading plastic artefacts presents particular problems
OpinionCompounding problems
Regulating the line between a vital service and grey-market profiteering is a mess
OpinionSlow march of the retrosynthesis robots
Software synthesis suggestions are hampered by biased and incomplete datasets
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways